Back to search results

A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

Abroad (travel likely)RecruitingPHASE1

Conditions

Non-small Cell Lung Cancer · Head and Neck Squamous Cell Carcinoma · Colorectal Carcinoma · Pancreatic Adenocarcinoma · Breast Cancer · Other Solid Tumors · Ovarian Cancer · Myeloid Neoplasms (AML/MDS)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Research Site, Gilbert, Arizona, United States

  • Research Site, Duarte, California, United States

  • Research Site, Newport Beach, California, United States

  • Research Site, Santa Monica, California, United States

  • Research Site, Jacksonville, Florida, United States

  • Research Site, Miami, Florida, United States

  • Research Site, Tampa, Florida, United States

  • Research Site, Boston, Massachusetts, United States

  • Research Site, New Brunswick, New Jersey, United States

  • Research Site, New York, New York, United States

  • Research Site, Charlotte, North Carolina, United States

  • Research Site, Winston-Salem, North Carolina, United States

  • Research Site, Portland, Oregon, United States

  • Research Site, Pittsburgh, Pennsylvania, United States

  • Research Site, Nashville, Tennessee, United States

  • Research Site, Houston, Texas, United States

  • Research Site, Round Rock, Texas, United States

  • Research Site, Milwaukee, Wisconsin, United States

Study leads

  • AstraZeneca

    Study Director

    AstraZeneca

View source on ClinicalTrials.gov(opens in a new tab)